Decitabine for Poor Graft Function Post Allo-HSCT
ConditionPoor Graft Function
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age16-70
SponsorThe First Affiliated Hospital of Soochow University
About this trial
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
Eligibility criteria
Qualifiers
Diagnosed as PGF at day 28 post-HSCT or later. PGF was defined as two or three cytopenias, absolute neutrophil count ≤ 1.5 × 109/L, platelet count ≤ 30 × 109/L, hemoglobin ≤ 85g/L, lasting for more than 2 consecutive weeks;
Full donor chimerism;
Primary disease in remission;
No severe GVHD and relapse;
Disqualifiers
Allergic to decitabine;
Active infections;
Uncontrolled GVHD;
Severe organ dysfunction;
Trial design
Treatments tested in this trial
- Decitabine
- Granulocyte Colony-Stimulating Factor
- Thrombopoietin Receptor Agonist
- Recombinant human erythropoietin
Treatment groups
76 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov